IL-34 Antikörper (Biotin)

Produktnummer ABIN2660792

Dieses Maus Monoklonal-Antikörper erkennt spezifisch IL-34 in FACS. Er zeigt eine Reaktivität gegenüber Human.

Kurzübersicht für IL-34 Antikörper (Biotin) (ABIN2660792)

Target: IL-34 (IL34) (Interleukin 34 (IL34))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser IL-34 Antikörper ist konjugiert mit Biotin

Applikation: Flow Cytometry (FACS)

Klon: E033B8

Produktdetails anti-IL-34 Antikörper (Biotin)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with biotin under optimal conditions. The solution is free of unconjugated biotin.

Isotyp: IgG2a lambda

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu IL-34

Target: IL-34 (IL34) (Interleukin 34 (IL34))

Andere Bezeichnung: IL-34

Hintergrund: Human IL-34 shares a sequence identity of 99.6 % , 72 % and 71 % with chimpanzee, rat, and mouse IL-34, respectively, on the amino acid level. The IL-34 gene is syntenic in the human, chimpanzee, rat, and mouse genomes. IL-34 has no apparent consensus structural domain or motif, and does not share sequence homology with M-CSF, nevertheless, it binds to the CSFR. These two cytokines are not identical in biological activity and signal activation. IL-34 and CSF show an equivalent ability to support cell growth or survival. However, these cytokines are differing in their ability to induce the production of chemokines (MCP-1 and eotaxin-2) in primary macrophages, the morphological change in TF-1-fms cells, and the migration of J774A.1 cells. The use of monoclonal antibodies against the CSFR suggests differential domain binding of the receptor to IL-34 and CSF and as a result, different bioactivities and signal activation kinetics/strength are produced for these cytokines.

Pathways: RTK Signalweg